BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 37377903)

  • 1. Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome.
    Subasri V; Light N; Kanwar N; Brzezinski J; Luo P; Hansford JR; Cairney E; Portwine C; Elser C; Finlay JL; Nichols KE; Alon N; Brunga L; Anson J; Kohlmann W; de Andrade KC; Khincha PP; Savage SA; Schiffman JD; Weksberg R; Pugh TJ; Villani A; Shlien A; Goldenberg A; Malkin D
    Cancer Res Commun; 2023 May; 3(5):738-754. PubMed ID: 37377903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Predicted Effects of
    Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
    Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
    J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
    Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
    J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
    Kamihara J; Rana HQ; Garber JE
    Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited
    Guha T; Malkin D
    Cold Spring Harb Perspect Med; 2017 Apr; 7(4):. PubMed ID: 28270529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
    Ariffin H; Hainaut P; Puzio-Kuter A; Choong SS; Chan AS; Tolkunov D; Rajagopal G; Kang W; Lim LL; Krishnan S; Chen KS; Achatz MI; Karsa M; Shamsani J; Levine AJ; Chan CS
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15497-501. PubMed ID: 25313051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.